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Sunlight and health
Use of sunscreens does not risk vitamin
D deficiency
Editor—Ness et al misinterpret our work in
Australia by stating that we showed that use
of sunscreens reduced vitamin D concentra-
tions.1 In fact, we showed that the use of sun-
screens did not prevent the normal summer
rise in 25-hydroxy vitamin D concentration
(the vitamin D fraction that is used to assess
vitamin D deficiency).2 Subjects using sun-
screens compared with controls using a
placebo cream had an equal rise over the
summer.
As an extension of the study we also
measured concentrations of 1,25-hydroxy
vitamin D. This fraction of vitamin D is
believed to be regulated by 25-hydroxy
vitamin D concentrations via a negative
feedback mechanism. We found a rise in
1,25-hydroxy vitamin D concentrations over
the summer in people using sunscreen, but
the rise was smaller than that among those
using placebo. In a small group there was a
lower, but not significantly different, concen-
tration of 1,25-hydroxy vitamin D at the end
of summer. However, this occurred in the
presence of a substantial rise in 25-hydroxy
vitamin D concentrations (the vitamin D
fraction that controls 1,25-hydroxy vitamin
D) in all subjects. We also made it clear in
our paper that the 1,25-hydroxy vitamin D
concentrations of all the participants in the
placebo and sunscreen groups remained
within the normal range all the way through
the study.
It is mischievous and specious to imply
that our work was suggesting that use of
sunscreen might lead to vitamin D defi-
ciency. We made the opposite point very
strongly in the paper and clearly explained
why, in the presence of raised 25-hydroxy
vitamin D concentrations, the slightly
smaller changes in 1,25-hydroxy vitamin D
could not be interpreted as a risk for vitamin
D deficiency.
Robin Marks professor of dermatology
St Vincents Hospital, Melbourne, Fitzroy Victoria
3065, Australia
ebejerjd@svhm.org.au
1 Ness AR, Frankel SJ, Gunnell DJ, Smith DG. Are we really
dying for a tan? BMJ 1999;319:114-6. (10 July.)
2 Marks R, Foley PA, Jolley D, Knight, KR, Harrison J,
Thompson SC. The effect of regular sunscreen use on vita-
min D levels in an Australian population. Arch Dermatol
1995;131:415-21.
Article did not help informed debate
Editor—Debating the content of health
education messages, the scientific evidence
on which they are based, and their likely
effects, both bad and good, is important pro-
vided that the debate is constructive and
based on a sound literature review. Unfortu-
nately the article by Ness et al inadequately
addresses the debate about sun protection.1
The article opens with the statement
that certain professionals embrace the
notion that “sunlight is bad for health,”
implying that the message has been to avoid
sun exposure. This misrepresents the advice
given, which includes “avoiding excessive
sun exposure” and “encouraging gradual
sun exposure.”2
No short article can do justice to the
extensive research, both epidemiological
and experimental, into the role of exposure
to ultraviolet radiation in the aetiology of
skin cancer. The limitations and uncertain-
ties about our understanding of the problem
have been the subject of international, inter-
disciplinary debate. The dilemma facing
those who wish to prevent extensive
morbidity from skin cancer, and rising mor-
tality from melanoma, is that effective
primary prevention may take 20 years or
more to reduce the incidence of disease. As
is the case with the prevention of other
diseases, there has been much pressure to
promote lifestyle and dietary changes.
Ness et al suggest that early detection
and treatment may be more beneficial than
primary prevention in reducing mortality
from melanoma, but in countries with a low
incidence of melanoma we have yet to agree
on a cost effective strategy for early
detection.3 4 Nor do the authors address the
psychological and financial costs of diagno-
sis and treatment.
Primary prevention undoubtedly brings
costs as well as benefits. However, there is
insufficient evidence at this stage for Ness et
al to suggest that recommendations on sun
exposure should be promoted to prevent
one disease at the expense of another. It may
well be that greater understanding of the
problem will enable development of recom-
mendations on sun exposure that can
benefit more than one condition.
It is essential that people should have
the opportunity to make fully informed
choices about their lifestyles and that
decisions on prevention are based on the
best available evidence. Although Ness et al
raise important questions about how best to
prevent skin cancer, from an epidemiologi-
cal view the article is disappointing because
it has not adequately reviewed all the health
issues and because it has misrepresented at
least two studies.2 5
Jane Melia epidemiologist
Cancer Screening Evaluation Unit, Institute of
Cancer Research, Sutton, Surrey SM2 5NG
melia@icr.ac.uk
1 Ness AR, Frankel SJ, Gunnell DJ, Davey Smith G. Are we
really dying for a tan? BMJ 1999;319:114-6. (10 July.)
2 Melia J. Skin cancer. Health Hygiene 1995;16:153-8.
3 Sinclair R. Commentary: Start with the KISS principle.
BMJ 1998;316:38-39.
4 Melia J. Changing incidence and mortality from cutaneous
malignant melanoma: the reasons are not yet clear. BMJ
1997;315:1106-7.
5 Marks R, Foley PA, Jolley D, Knight KR, Harrison J,
Thompson SC. The effect of regular sunscreen use on vita-
min D levels in an Australian population. Arch Dermatol
1995;131:415-21.
Not all sunlight is dangerous, just
ultraviolet radiation
Editor—By referring to just sunlight rather
than its individual components, Ness et al
apparently fail to understand the message
which photobiologists and dermatologists
have been seeking to put to the public for
many years.1 Sunlight, as the authors imply,
is indeed essential to life, but its warmth and
light are all we need. The third component,
ultraviolet radiation, is universally harmful
to the skin, although usually not noticeably
so in the early years of life.
Advice to authors
We prefer to receive all responses electronically,
sent either directly to our website or to the
editorial office as email or on a disk. Processing
your letter will be delayed unless it arrives in an
electronic form.
We are now posting all direct submissions to
our website within 24 hours of receipt and our
intention is to post all other electronic
submissions there as well. All responses will be
eligible for publication in the paper journal.
Responses should be under 400 words and
relate to articles published in the preceding
month. They should include <5 references, in the
Vancouver style, including one to the BMJ article
to which they relate. We welcome illustrations.
Please supply each author’s current
appointment and full address, and a phone or
fax number or email address for the
corresponding author. We ask authors to declare
any competing interest. Please send a stamped
addressed envelope if you would like to know
whether your letter has been accepted or rejected.
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Now that we live much longer, however,
exposure to ultraviolet radiation has
become of major importance. It causes
photoageing of skin in virtually everyone,
particularly the fair skinned, inducing a dry,
often itchy, wrinkled, blotchy, telangiectatic
effect,2 and skin cancer in a significant but
steadily increasing minority. About 50 000
people in the United Kingdom develop skin
cancer each year, nearly 2000 of whom die;
however, the number of cases is beginning
to fall in countries, such as Australia, where
community ultraviolet avoidance pro-
grammes are well established.3 The authors
assert that these death rates are not very
high and that only a small reduction will be
achieved by avoiding sunlight. Nevertheless,
any skin cancer is detrimental to the sufferer
and costly to health services, particularly
when preventive measures are readily
available. The high outlay on cosmetics and
surgery to repair photoageing could also be
significantly reduced.
Ness et al further state that mental health,
and particularly seasonal affective disorder, is
improved by sunlight. But this effect is by
exposure to the essentially harmless visible
light spectrum through the eye, not to
damaging ultraviolet radiation through the
skin.4 Similarly, vitamin D is readily available
in a normal diet, and not sunbathing is
unlikely to lead to a deficiency.5
What we must understand is that
ultraviolet radiation is the sunlight we must
avoid and that this is at its most intense
between about 11 am and 3 pm in Britain in
summer and all year round in tropical
climates, even on cloudy or cool days.
Adequate protection at such times can easily
be achieved by covering up with appropriate
clothing, seeking the shade when possible,
and using a high protection sunscreen on
exposed skin. At other times, however, even
in hot and sunny conditions, the ultraviolet
intensity is much weaker and less caution is
needed; if sunscreens are used the risk is
further minimised.
J L M Hawk professor of dermatological photobiology
Department of Photobioology, St Thomas’s
Hospital, London SE1 7EH
1 Ness AR, Frankel SJ, Gunnell DJ, Davey Smith G. Are we
really dying for a tan? BMJ 1999;319:114-6. (10 July.)
2 Herschenfield RE, Gilcrest RA. The cumulative effects of
ultraviolet radiation on the skin. In: Hawk JLM, ed.
Photodermatology. London: Arnold, 1999:69-87.
3 Staples M, Marks R, Giles G. Trends in the incidence of
non-melanocytic skin cancer (NMSC) treated in Australia
1985-1995; are primary prevention programs starting to
have an effect? Int J Cancer 1998;78:144-8.
4 Partonen T, Lonnqvist J. Seasonal affective disorder. Lancet
1998;352:1369-74.
5 Marks R, Foley PA, Jolley D, Knight KR, Harrison J,
Thompson SC. The effect of regular sunscreen use on vita-
min D levels in an Australian population. Arch Dermatol
1996;131:415-21.
Severity of effect depends on where you
live
Editor—Ness et al questioned the advice
given by public health authorities to reduce
exposure to sunlight.1 Without quantifying
the risks and benefits of sun exposure across
the population, the authors reasoned, isn’t it
unethical to advocate a change in behav-
iour? They then conducted a brief review of
known harms and possible benefits of
sunlight exposure and concluded that
increased exposure to the sun might be ben-
eficial when assessed on a population basis.
Predictably, the article has created a storm in
the lay press, but what of its scientific
content?
The question posed is certainly reason-
able. However, the article is flawed by super-
ficial interpretation, a disturbing tendency to
equate conjecture with evidence, and a
failure to appreciate the adverse effects of
sun exposure experienced by people living
in other parts of the world. For example, the
authors claim that reductions in mortality
from melanoma by reducing exposure to
the sun will be small and suggest that it
would be better to train the public to consult
doctors at an earlier stage in the disease
process. Even in countries with low rates of
melanoma, such as England and Wales,
these claims are contentious; when applied
to the sun ravaged populations of Australia,
New Zealand, and low latitude United States,
they are incomprehensible.
Two possible benefits of sunlight expo-
sure were expounded: a reduction in coron-
ary heart disease and improvements in
mood and wellbeing, although the evidence
proffered for these claims was extremely
weak. Assuming that high levels of sunlight
exposure are beneficial, then at the crudest
level fair skinned Australians might be
predicted to have lower cardiovascular mor-
tality and fewer suicides than their northern
European cousins. However, death rates for
heart disease among Australian men in the
MONICA cohorts are higher than those for
Iceland, Denmark, or Sweden,2 and suicide
rates in Australia are among the highest in
the world.3 Moreover, people who migrate
from England, Wales, and Ireland to
Australia commit suicide at higher rates
than those who remain behind.4
Most people would agree that simple
health education messages are blunt tools
for addressing complex health problems,
but I wonder about the consequences of the
high profile strategy adopted by Ness et al.
The distilled message of the article
(intended or otherwise) that “sunlight is
good for you” will echo far beyond the lush
pastures of the Avon valley into dusty,
sunburnt townships half a world away. It is
here that the damage will be done.
David C Whiteman Nuffield medical research fellow
Imperial Cancer Research Fund General Practice
Research Group, Institute of Health Sciences,
University of Oxford, Oxford OX3 7LF
david.whiteman@dphpc.ox.ac.uk
1 Ness AR, Frankel SJ, Gunnell DJ, Davey Smith G. Are we
really dying for a tan? BMJ 1999;319:114-6. (10 July.)
2 Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D,
Rajakangas AM, Pajak A. Myocardial infarction and coron-
ary deaths in the World Health Organization MONICA
project. Registration procedures, event rates, and case-
fatality rates in 38 populations from 21 countries in four
continents. Circulation 1994;90:583-612.
3 La-Vecchia C, Lucchini F, Levi F. Worldwide trends in
suicide mortality, 1955-1989. Acta Psychiatr Scand 1994;90:
53-64.
4 Burvill PW. Migrant suicide rates in Australia and in coun-
try of birth. Psychol Med 1998;28:201-8.
Exposure to sunlight may reduce cancer
risk
Editor—The criticism of Ness et al’s article
questioning the acceptance of sunlight as
being bad for health1 in the lay press
underlines how the authors have dared to
question one of the axiomatic tenets of mod-
ern preventive medicine. Sunlight exposure is
viewed as one of the major avoidable causes
of cancer, ranking alongside cigarette smok-
ing in the demonology of medicine. It is
therefore surprising that the authors did not
consider the evidence that, far from causing
cancer, sunlight exposure might actually be a
potent agent for its prevention.
Several studies have examined the
relation between sunlight exposure and
internal malignancy. Several of these give
sufficient information to allow the effect of
changing sunlight exposure on the expected
rate of malignancy to be estimated. All the
studies show a negative relation of similar
magnitude (table), particularly for breast
and colon cancer.
In 1995 there were about 30 000 new
cases each of breast and large bowel cancer
in the United Kingdom and about 30 000
deaths from the two tumours combined.
The most conservative of the estimates from
the above studies suggest that a 10%
decrease in sunlight exposure might lead to
a 6% increase in these figures. This would
approximate to 1800 extra cases of each of
the tumours and 1800 extra cancer deaths.
This figure exceeds the total number of
deaths due to malignant melanoma, which
are unlikely to be totally prevented by such a
modest reduction in sunlight exposure.
Thus, reducing exposure to solar radia-
tion, far from preventing cancer, may have
the opposite effect. Further research is
urgently needed to determine whether this
is the case. If the increase is confirmed it will
be necessary to determine what aspect of
sunlight protects against cancer. Vitamin D
or its metabolites may play an important
part, offering hope for a strategy of
moderating sunlight exposure to minimise
the risk of skin cancer but replacing vitamin
D to prevent internal malignancy.
Peter L Selby lecturer in medicine
Peter.Selby@man.ac.uk
E Barbara Mawer professor
Department of Medicine, Manchester Royal
Infirmary, Manchester M13 9WL
Increases in incidence of breast and colonic cancer associated with 10% decrease in sunlight at mean
exposure
Study Site Country Increase in incidence (%)
Garland and Garland, 19802 Colon United States 12
Garland et al, 19903 Breast United States 6
Gorham et al, 19904 Breast Russia 10
Emerson and Weiss, 19925 Colon United States 7
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1 Ness AR, Frankel SJ, Gunnell DJ, Davey Smith G. Are we
really dying for a tan? BMJ 1999;319:114-6. (10 July.)
2 Garland CF, Garland FC. Do sunlight and vitamin D
reduce the likelihood of colon cancer? Int J Epidemiol
1980;9:227-231
3 Garland FC, Garland CF, Gorham ED, Young JF.
Geographic variation in breast cancer mortality in the
United States: A hypothesis involving exposure to solar
radiation. Prev Med 1990;19:614-22
4 Gorham ED, Garland FC, Garland CF. Sunlight and
breast cancer incidence in the USSR. Int J Epidemiol
1990;19:820-824
5 Emerson JC, Weiss NS. Colorectal cancer and solar radia-
tion. Cancer Causes and Control 1992;3:95-9.
Authors’ reply
Editor—Exposure to sunlight clearly is not
unequivocally noxious, as has been observed
by others.1 2 Our article was an attempt to
consider harm in the context of some
potentially protective effects and to suggest
that health education messages may be less
fragile if a more balanced portrayal of risk
and benefit is offered to the public than is
sometimes the case. The intemperate tone
of some of the responses to our article
shows how some issues can become more
sectarian than scientific.
Turning to the substantive points raised,
Marks and Melia suggest that we have
misrepresented the results of a randomised
controlled trial of sunscreens.3 In this study
113 adults living in Victoria, Australia, were
randomised to either sunscreen or placebo
over the course of an Australian summer.
Concentrations of 25-hydroxy vitamin D
and 1,25-hydroxy vitamin D were measured
at the beginning and end of the study. The
rise in 25-hydroxy vitamin D concentrations
was similar in both groups, but the rise in
1,25-hydroxy vitamin D was lower in those
allocated to receive sunscreen: a 1.5%
increase from baseline versus a 13.3%
increase (P = 0.009). To call this “a slightly
smaller change,” as Marks does, is surely
misleading. This study population was
exposed to much stronger sunlight than
that in temperate climates; furthermore, the
sample studied probably experienced a
higher than average sun exposure for
Australians as they had a history of solar
keratoses. Despite these characteristics the
study provides evidence that sunscreens
may affect vitamin D values. An extreme
example of the danger of extrapolating
from the Australian experience to less
sunny climates is provided by the recent
report of a case of rickets in a white child
in Toronto who had been covered in
sunscreen.4
Whiteman points out that we focused on
a British population. Clearly, the balance of
risks and benefits will differ between climates
and populations, and the appropriate public
health message will vary. Whiteman also
suggests that because exposure to sunlight
does not explain several population differ-
ences in disease risk it cannot be important.
This observation ignores the multifactorial
nature of the aetiology of melanoma, and
many examples—such as the high male
smoking rate and very low coronary heart
disease rate in Japan—show the misplaced
reassurance that can follow from such com-
parisons. Selby and Mawer draw our
attention to the evidence that exposure to
sunlight may in fact reduce risk of some
cancers. Although this evidence is tentative,
it supports our contention that more
sophisticated risk-benefit analyses are
required in the formulation of public health
policy.
Andrew R Ness senior lecturer in epidemiology
Stephen J Frankel professor of epidemiology and
public health medicine
David J Gunnell senior lecturer in epidemiology
George Davey Smith professor of clinical
epidemiology
Department of Social Medicine, University of
Bristol, Bristol BS8 2PR
1 Diffey BL. Sun protection: have we gone too far? Br J
Derm 1998;138:544-64.
2 Report of the Subgroup on Bone Health, Working
Group on the Nutritional Status of the Population of the
Committee on Medical Aspects of Food and Nutrition
Policy. Nutrition and bone health. London: Stationery
Office, 1998:3. (Recommendation 18.)
3 Marks R, Foley PA, Jolley D, Knight KR, Harrison J,
Thompson SC. The effect of regular sunscreen use on
vitamin D levels in an Australian population. Arch Derm
1995;131:415-21.
4 Zlotkin S. Vitamin D concentrations in Asian children liv-
ing in England. BMJ 1999;318:1417. (22 May.)
Intervention trial for late life
depression defended
Editor—We would like to respond to
several criticisms of our study1 raised in
Haynes’s editorial2 and in Deeks and
Juszczak’s commentary.3
Haynes argues that our study is limited
by patients refusing to participate or
dropping out. In the context of studies in
elderly people, we think that our refusal and
follow up rates were reasonable. It is difficult
to recruit elderly people into research stud-
ies4 and maintain their participation. Con-
siderable drop out rates were expected
because our sample consisted of frail older
people, many of whom died or became too
ill to participate.
Haynes considers that our difficulty in
recruiting and retaining doctors and
patients compromised our community
based intervention. Although maximising
participation is important, the practical
difficulties of fully engaging a community
of busy doctors and frail elderly people
needs acknowledgment. The educational
programme was attended by the general
practitioners of 62% of the participants in
the intervention group and by 35 of the 71
(49%) general practitioners caring for the
1036 residents interviewed. These attend-
ance rates are above average for continuing
medical education in general practice.
Although 28% of participants in the
intervention group attended exercise
classes, remember that we sought to reach
old, frail, depressed people unlikely to
exercise. Furthermore, by design, we did
not specifically target participants in the
study.
Haynes is concerned that the interven-
tion’s effect was at the expense of additional
resources. Although some additional
resources were required, the intervention
was not expensive to run. To enhance gener-
alisability and sustainability we used existing
resources whenever possible. Apart from
having a full time project officer funded by a
grant, the intervention project was encom-
passed within the other people’s usual posi-
tions. As the educational materials have
been devised, the intervention could be
implemented at a similar site with reason-
able healthcare resources for the cost of this
position.
Deeks and Juszczak’s commentary out-
lines four “deficiencies” that may have
affected our findings but seems to conclude
that only the lack of a concurrent control
group is likely to have introduced bias. We
considered these limitations at the outset,
but there was no sensible, practical alterna-
tive design. Whereas the standard ran-
domised controlled trial design is undeni-
ably valuable, the value should be weighed
against the methodological difficulties of
health services research.
If undue weight is given to these
criticisms our study’s important clinical mes-
sage may be lost. Late life depression is an
important public health problem. The effect
of intervention was modest but significant.
Despite the methodological issues raised,
this intervention is a promising way of
addressing late life depression in residential
care.
Robert H Llewellyn-Jones lecturer
rljones@mail.usyd.edu.au
Karen A Baikie senior research officer
Healthy Aging Research Unit, Hornsby Ku-ring-gai
Hospital, Hornsby, New South Wales, 2077,
Australia
1 Llewellyn-Jones RH, Baikie KA, Smithers H, Cohen J,
Snowdon J, Tennant CC. Multifaceted shared care
intervention for late life depression in residential care:
randomised controlled trial. BMJ 1999;319:676-682. (11
September.)
2 Haynes B. Can it work? Does it work? Is it worth it? BMJ
1999;319:652-653. (18 September.)
3 Deeks JJ, Juszczak E. Commentary: Beyond the boundary
for a randomised controlled trial? BMJ 1999;319:682. (11
September.)
4 Cameron ID. Recruiting older people for clinical trials and
health promotion programs. Med J Aust 1997;167:441.
Design of CRASH trial
Evidence shows that quality of trial by
Faupel et al is good and therefore should
not be excluded
Editor—Gregson et al re-analyse the meta-
analysis in the systematic review of cortico-
steroids for acute traumatic brain injury
published in the BMJ in 1997, of which I was
first author.1 2 They present an argument for
excluding from the analysis the trial with the
most beneficial results,3 thus making the
point estimate for the meta-analysis move
towards no effect. They use this to condemn
the CRASH trial, which is aimed at resolving
the uncertainty over the effects of steroids in
brain injury.
The systematic review was also pub-
lished in the Cochrane Library, where it is
periodically updated to take account of the
results of ongoing searches for studies.4 As
well as identifying three more small trials
presenting data on deaths, we have found
more publications reporting the trial by
Faupel et al. As detailed in the original
Letters
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review, the quality score given to this trial
meant that we were unclear about how allo-
cation concealment was ensured (not “poor
quality” as suggested by Gregson et al). From
one publication5 we now have more detail
on the procedures used and would classify
their use of coded identical vials as adequate
quality, or class A. This information will be
included in the next update of the review. So
there is no reason to exclude this trial on the
basis of the quality of allocation conceal-
ment as Gregson et al suggest.
Their other argument for ignoring the
trial by Faupel et al is that it measured
outcomes at discharge, whereas most other
trials look at longer term outcomes. We will
never know what the outcome of the trial
would have been at six months—the
apparent benefit of steroids may have
decreased, or it could have increased. We
judged it better to include the results in the
meta-analysis rather than exclude it on the
basis of speculation.
Even with their analysis Gregson et al
are quite wrong to state that “any possible
benefit [of corticosteroids] is eliminated”—
the confidence interval still includes a
clinically important benefit. We are left with
continuing uncertainty over the effect of
steroids. This cannot be resolved by
re-analysis of existing data—only by the
addition of more data from large ran-
domised trials.
Phil Alderson associate director
UK Cochrane Centre, Oxford OX2 7LG
palderson@cochrane.co.uk
1 Gregson B, Todd NV, Crawford D, Gerber CJ, Fulton B,
Tacconi L, et al. CRASH trial is based on problematic
meta-analysis. BMJ 1999;319:578. (28 August.)
2 Alderson P, Roberts I. Corticosteroids in acute traumatic
brain injury: systematic review of randomised controlled
trials. BMJ 1997;314:1855-9.
3 Faupel G, Renlen HJ, Muller D, Schurmann K. Double-
blind study on the effects of steroids on severe closed head
injury. In: Pappius MM, Feindel W, eds. Dynamics of brain
edema. Berlin: Springer Verlag, 1976:337-43.
4 Alderson P, Roberts I. Corticosteroids for acute traumatic
brain injury (Cochrane review). In: The Cochrane Library.
Issue 3. Oxford: Update Software, 1999.
5 Faupel G. The influence of dexamethasone on the
midbrain syndrome after severe head injury. In: Hart-
mann, Brock M, eds: Treatment of cerebral edema. Berlin:
Springer Verlag, 1982:107-14.
Trial is best way to elucidate effectiveness
of corticosteroids in acute severe head
injury
Editor—Corticosteroid treatment for acute
severe head injury could well reduce the risk
of death or severe disability by a few per
cent—for example, from 15% to 13%—and
Gregson et al would then be wrong to
describe such a benefit as “vanishingly
small.”1 The CRASH trial (corticosteroid
randomisation after significant head injury)
seeks to randomly allocate many thousands
of patients to a 48 hour infusion of
methylprednisolone or placebo to obtain
reliable evidence on whether corticosteroid
has a small but real net benefit.2 If there is,
then hundreds of thousands of future
patients could be given this treatment,
protecting several thousands from disaster.
Moreover, because corticosteroids are rou-
tinely given to patients with head injury in
many parts of the world, reliable refutation
of a benefit could protect thousands of
patients from unnecessary corticosteroid
administration.3 The corticosteroid regimen
to be tested in CRASH is similar to that
already tested in the NASCIS-2 trial, which
showed that such treatment safely produced
significant net benefit in acute injury of the
spinal cord.4
The CRASH protocol references evi-
dence from animal experiments showing
possible benefit; it also references the possi-
bility of side effects, the evidence from
NASCIS-2 that this treatment regimen
helps patients with an acute spinal cord
injury, and, of course, the previous such
trials in acute head injury.2 In doing so,
however, it merely claims that, both
separately and collectively, those previous
trials randomly allocated too few patients to
be able to assess a net benefit of “only” a few
per cent. The protocol explicitly states that
those previous trial results are compatible
with the existence of a small net benefit, no
net benefit, or even a small hazard, and this
remains true whether Gregson et al
selectively remove one or a few of those old,
small trials.
The uncertainty principle governs entry
to the CRASH trial: patients are eligible for
randomisation only if the responsible doctor
is substantially uncertain about whether they
should be offered steroids.5 Use of the
uncertainty principle simplifies the entry
criteria and makes randomisation easier to
justify to ethics committees. More impor-
tantly, if corticosteroids really can slightly
improve the prognosis among patients with
significant head injury, then it would be
unethical not to get reliable evidence of this.
The CRASH trial is the best way to seek such
evidence.
Ian Roberts CRASH trial clinical coordinator
On behalf of the CRASH Trial Management
Group, CRASH Coordinating Centre, Institute of
Child Health, London WC1N 1EH
Ian.Roberts@ich.ucl.ac.uk
1 Gregson B, Todd NV, Crawford D, Gerber CJ, Fulton B,
Tacconi L, et al. CRASH trial is based on problematic
meta-analysis. BMJ 1999;319:578. (28 August.)
2 CRASH, corticosteroid randomisation after significant
head injury. www.crash.ucl.ac.uk/
3 Wang Z, Jiang J. Current status of trauma care in China.
Trauma Q 1999;14:233-40.
4 Bracken MB, Shepard MJ, Collins WF, Holford TR, Young
W, Baskin DS, et al. A randomized, controlled trial of
methylprednisolone or naloxone in the treatment of acute
spinal-cord injury. Results of the second national acute
spinal cord injury study. N Engl J Med 1990;322:1405-11.
5 Peto R, Baigent C. Trials: the next 50 years. BMJ
1998;317:1170-1.
Routine antenatal HIV testing
Is justified in areas of low HIV
prevalence
Editor—The recent papers by Postma et al
and Simpson et al highlight the difficult
issues in establishing a policy to test for HIV
infection in antenatal clinics.1 2
Postma et al’s paper examines the cost
effectiveness of universal, voluntary testing
of pregnant women in England in terms of
healthcare costs to the NHS. Although no
cut off point at which the cost for each life
year gained becomes acceptable has been
defined for England, a cut off point of
around $50 000 is suggested in the United
States. They conclude that in areas of high
prevalence, such as London, universal,
voluntary antenatal screening of pregnant
women is cost effective; how- ever, in areas
of low prevalence, screening may not be
justified in terms of cost effectiveness.
Screening for HIV infection in ante-
natal clinics fulfils most of Wilson and
Junger’s criteria as a good test.3 HIV
infection can be asymptomatic; the tests are
simple, relatively pain free, sensitive and
specific; and there is effective treatment that
can substantially reduce the risk of infection
in the fetus. Yet universal testing is not per-
formed in most antenatal clinics. This
contrasts with the ad hoc way in which uni-
versal screening for Down’s syndrome has
been introduced in most antenatal clinics—
yet none of the individual tests currently
available fulfil many of Wilson and Junger’s
criteria. Tests which are of low risk to the
fetus are not very sensitive or specific. In
spite of their unproved record, tests are
available, sometimes with the patient bear-
ing the cost of testing.
There is stigma surrounding HIV
testing; an opt-in policy serves only to
reinforce this by testing only those in
obvious high risk groups. In low prevalence
areas, where there are not large numbers of
“high risk” women, those with HIV infection
may be even harder to detect from a screen-
ing questionnaire as they mingle with the
rest of the population. In Portsmouth a third
of our HIV positive patients do not fall into
any recognised high risk group. Simpson et
al’s paper shows that for an effective screen-
ing programme to be instigated, an opt-out
policy of testing is the only model which is
effective in antenatal screening; the uptake
of the test increased to 88% compared with
a 35% uptake with an opt-in policy. This
policy should be adopted not only for areas
of high prevalence of HIV testing but also
for areas where the prevalence of HIV infec-
tion is low, so that the opportunity to reduce
infection in the neonate and treat the
asymptomatic mother is not missed.
Elizabeth Foley specialist registrar
V Harindra consultant
Department of Genitourinary Medicine, St Mary’s
Hospital, Portsmouth PO3 6AD
1 Postma MJ, Beck EJ, Mandalia S, Sherr L, Walters MDS,
Houweling H, Jager JC. Universal HIV screening of preg-
nant women in England: cost effectiveness analysis. BMJ
1999;318:1656-60. (19 June.)
2 Simpson WM, Johnstone FD, Goldberg DJ, Gormley SM,
Hart GJ. Antenatal HIV testing: assessment of a routine
voluntary approach. BMJ 1999;318:1660-1. (19 June.)
3 Wilson JMG, Junger JJ. Principles and practice of screening
for disease. Geneva: World Health Organisation, 1968:34.
Is acceptable to women
Editor—Simpson et al describe a large
increase in the uptake of antenatal HIV test-
ing following a change from an opt-in
approach to routine testing unless the
woman declined.1 Their study took place in
Edinburgh, and they questioned whether
the outcome would be similar in London,
Letters
1069BMJ VOLUME 319 16 OCTOBER 1999 www.bmj.com
with its greater cultural and linguistic
complexities.
We would like to report our experience
of changing the process for antenatal HIV
testing in a deprived, multicultural London
population with a high prevalence of HIV
infection among pregnant women (0.86% in
1998; Public Health Laboratory Service,
unpublished data). An antenatal HIV testing
programme was originally introduced in
June 1995; women were offered a test, with
signed consent, after discussion with mid-
wives. Despite staff training and support,
uptake of testing increased only from 25%
to 33% by 1998, and uptake varied widely
between individual midwives.2
In 1998 HIV testing was integrated into
the recommendation of all routine antenatal
screening for infection. The new policy was
launched on World AIDS Day, 1 December,
resulting in supportive local publicity.
Currently an updated leaflet giving infor-
mation about hepatitis B, syphilis, rubella,
and HIV infection is sent to women before
booking. Discussion and women’s decisions
about the tests are summarised without a
requirement for signed consent. Copies of
all negative results are sent to women for
inclusion in their handheld notes. Positive
results of tests for HIV antibody are given by
a consultant obstetrician in conjunction with
a health adviser.
The new policy resulted in a rise in
uptake in December 1998 to 197/241 (82%)
of women booked through the antenatal
clinic. This has been sustained, with an over-
all uptake of 1440/1605 (90%) in the first six
months for antenatal clinic attendees;
community figures are currently being
analysed. Antenatal HIV testing identified
six infected women between December
1998 and April 1999; all are accepting inter-
ventions to minimise vertical transmission.
Women’s views were assessed by a ques-
tionnaire sent to all women who booked in
December 1998. The response rate was 39%,
with 88% of responders in favour of the HIV
test being recommended as a routine blood
test in pregnancy. The only negative
comments related to the length of time for
results to be received by post, and this has
since been dealt with.
HIV testing should be a routine part of
antenatal care. In our experience this is
acceptable to women and results in a
dramatic increase in uptake.
Maggie Blott consultant obstetrician
Jean Yearwood director of midwifery
Marie Gerval clinical research fellow
Jan Welch consultant in genitourinary medicine
King’s College Hospital, London SE5 9RS
Dr Mark Zuckerman consultant virologist
Public Health Laboratory Service, Dulwich
Hospital, London SE22 8PT
1 Simpson WM, Johnstone FD, Goldberg DJ, Gormley SM,
Hart GJ. Antenatal HIV testing: assessment of a routine
voluntary approach. BMJ 1999;318:1660-1. (19 June.)
2 Jones S, Sadler T, Low N, Blott M, Welch J. Does uptake of
antenatal HIV testing depend on the individual midwife?
Cross sectional study. BMJ 1998;316:272-3.
Influence of data display
formats on decisions to stop
clinical trials
Paper is misleading, like a sheep dressed
in a wolf ’s clothing
Editor—The abstract of Elting et al’s paper
gave the impression that icon displays
resulted in significantly more correct deci-
sions than did tables (P = 0.03).1 In fact, the P
value of 0.03 applies only to the comparison
between icon displays and bar graphs or pie
charts. The P value for the comparison
between icon displays and tables is not
significant (P = 0.17 (p 1529)).
The study showed no significant differ-
ence between icon displays and tables for
time to make the decision (P = 0.81) or for
the quality of the decision. In view of this, the
abstract and discussion are deceptive.
James M Walker senior clinical information architect
Penn State College of Medicine, PO Box 850
(H-136), Herhey, PA 17033, USA
jmwalker@psghs.edu
1 Elting LS, Martin CG, Cantor SB, Rubenstein EB.
Influence of data display formats on physician investiga-
tors’ decisions to stop clinical trials: prospective trial with
repeated measures. BMJ 1999;318:1527-31. (5 June.)
Authors’ reply
Editor—The statement in the abstract
regarding the superiority of the icon display
is correct, as is the P value ascribed to the
comparison. This reflects the overall com-
parison among the four displays, using
Cochran’s Q test of the repeated measures
of correct decisions. This is reported in the
abstract and the results section because it
was the planned analysis of our primary
hypothesis. Exploratory, pairwise analyses
were also reported. Coincidentally, the P
values for the McNemar tests of the
difference between icon displays and the bar
charts or pie graphs were also 0.03; the P
value for the pairwise comparison between
the icon and table displays was 0.17.
The interpretation of the overall,
repeated measures test of the primary
hypothesis is straightforward. The accuracy
rate with icons was superior to that with the
other display methods, and the observed
difference was unlikely to have occurred by
chance. As is commonly the case with
exploratory analyses, however, interpret-
ation of the pairwise comparisons is an
exercise in explaining the results of under-
powered tests. The study was not powered to
test these hypotheses, and the P value of 0.17
for the difference between the icon displays
(82%) and table displays (68%) reflects the
small sample size. (The overall test included
136 observations, and the pairwise tests
included only 68.)
One could argue that a difference of
82% versus 68% and a P value < 0.20 in a
small sample warrant further study and that
in a larger sample this difference would be
significant. As the P value suggests, however,
one could argue equally strongly that there
is a 17% probability that the observed differ-
ence occurred by chance alone.
Unfortunately, no matter how one
explains the results of underpowered tests,
in statistics, as in sheep herding, it’s the size
of the flock that counts. The prudent reader
will cry wolf only in cases justified by
adequate sample sizes. Accordingly, we
remind readers to interpret the pairwise,
exploratory analyses in our study with
caution because of their low power.
Although underpowered for hypothesis
testing, the pairwise comparisons are useful
for hypothesis generation. As we have stated,
accuracy rates with table displays were inter-
mediate. Future studies should examine this
issue.
Linda S Elting associate professor of health services
research
Charles G Martin assistant professor of
biomathematics and medicine
Scott B Cantor assistant professor of health services
research
Edward B Rubenstein associate professor of medicine
Department of Medical Specialties, University of
Texas MD Anderson Cancer Center, 1515
Holcombe Boulevard–Box 40, Houston, TX
77030-4095, USA
lelting@notes.mdacc.tmc.edu
Fungal infections of skin and
nails of feet
Pragmatic clinical trial is now needed
Editor—The systematic review on topical
treatment for fungal infections of the feet
and the accompanying editorial by Finlay
illustrate the difficulties encountered when
the evidence shows that an alternative treat-
ment is both more effective and more
expensive.1 2 Finlay (a member of the
advisory board of Novartis, which manufac-
tures the more expensive allylamine treat-
ment) believes that we should give our
patients the most effective (and most expen-
sive) treatment. Hart et al provide purchas-
ers with a more balanced view by presenting
the costs of treating patients with an azole
initially followed by an allylamine against
the likely costs of treating all patients with
allylamines from the start.
I had always been led to believe that
topical terbinafine was vastly superior to
azoles in tinea pedis, but the systematic
review shows that cure rates were 80% and
72% respectively—not a vast difference in
absolute terms. So there is at least a case for
a policy of “try the cheaper one first and
then the more expensive one after” in an
NHS that has limited money to spend.
Wider debate is needed about whether the
inconvenience associated with such a policy
for the 8% of patients who might have been
cured if they had been given terbinafine in
the first place outweighs the savings.
Extrapolated on a national scale, the saving
of £155 per cohort of 100 patients could
save around £12.5m for the NHS as a whole,
even if only a tenth of those with fungal
infections of the foot sought medical
care—money that arguably could be better
spent.
One of the conclusions has to be that a
pragmatic clinical trial is now necessary to
test the model of azoles first then allylamine
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for treatment failures versus allylamines
throughout. Finlay suggests that patients will
simply not comply with four weeks’ treat-
ment whereas they would with one week’s
treatment, a hypothesis that is fully testable
in a pragmatic trial. Such a trial would also
answer the question of whether the 28% or
so of people who do not respond to azoles
initially will then respond to the allylamine
or whether they represent a subset with
resistant fungal species that fail to respond
to anything.
Those working for the NHS have a duty
not to accept automatically the most
effective and expensive treatment but to
question the evidence of gains and losses for
competing strategies. Far from being con-
fused by the evidence, patients and prescrib-
ers are now aware of exactly how much extra
benefit they may receive from different treat-
ment choices.
Hywel Williams professor of dermatoepidemiology
Centre of Evidence-Based Dermatology, Queen’s
Medical Centre NHS Trust, University Hospital,
Nottingham NG7 2UH
1 Hart R, Bell-Syer EM, Crawford F, Torgerson DJ, Young P,
Russell I. Systematic review of topical treatments for fungal
infections of the skin and nails of the feet. BMJ
1999;319:79-82. (10 July.)
2 Finlay AY. Skin and nail fungi—almost beaten. BMJ
1999;319:71-2. (10 July.)
Authors of meta-analysis defend their
view
Editor—Finlay’s editorial accompanied our
systematic review of topical treatments for
fungal infections of the skin and nails of the
feet.1 2 We agree with the author that it is
important to review the evidence for topical
treatment in parallel with that for oral treat-
ment. Indeed, our group is currently
completing separate systematic reviews of
oral treatments for fungal infections of the
skin of the feet and for fungal infections of
the nails of the feet.
We are concerned that Finlay’s main
source of evidence for topical allylamines in
the treatment of topical dermatophyte
infection seems to be a single trial of terbin-
afine for one week compared with clotrima-
zole for four weeks.3 We excluded this report
from our review because the data had
already been published.4 Furthermore, the
results were not entirely consistent with
those of another trial with the same first
author. This found no significant difference
between four weeks of naftifine, another
allylamine, and four weeks of clotrimazole
and hydrochloride.5
To overcome such competing claims
from different trials, meta-analysis pools all
relevant data. Our estimate of the effective-
ness of allylamines relative to azoles summa-
rises the 12 randomised trials that met strict
criteria. Aggregated data from 1450 patients
show allylamines to be 8% more effective
than azoles2—a smaller difference than that
in Finlay’s selected trial with only 200 of
these patients.3
We agree with Finlay that recommenda-
tions about treatment in clinical practice
should be based on all the relevant available
evidence. To our robust evidence about
efficacy we therefore added the identifiable
costs of prescribing and dispensing the
drugs being compared. To fill the gap in evi-
dence about patients’ adherence to these
drugs, however, further rigorous research is
needed in the form of pragmatic (or phase
3) randomised trials. Common sense alone
cannot be used to infer how adherence
differs between these drugs.
In short, we dispute Finlay’s advice that
all patients with topical dermatophyte infec-
tion should be treated with topical terbin-
afine. If pharmacists and podiatrists were to
follow this advice many patients who could
be cured by antifungal cream available over
the counter would consult their general
practitioners unnecessarily. It is prudent to
reserve allylamines for those infections that
do not respond to cream available over the
counter, at least until good evidence shows
that adherence differs substantially between
these drugs.
Rachel Hart research podiatrist
Faculty of Community Health Sciences, University
of Wales Institute Cardiff, Cardiff CF5 2SG
Sally E M Bell-Syer research fellow
Fay Crawford MRC fellow
PhilipYoung lecturer in biostatistics
Ian Russell professor of health sciences
Department of Health Sciences and Clinical
Evaluation, University of York YO10 5DD
David J Torgerson senior research fellow
Centre for Health Economics, University of York
1 Finlay AY. Skin and nail fungi—almost beaten. BMJ
1999;319:71-2. (10 July.)
2 Hart R, Bell-Syer SEM, Crawford F, Torgerson DJ, Young
PJ, Russell IT. Systematic review of topical treatments for
fungal infections of the skin and nails of the feet. BMJ
1999;319:79-82. (10 July.)
3 Evans EVG A comparison of terbinafine (Lamisil) 1%
cream given for one week with 1% clotrimazole (Canestan)
given for four weeks in the treatment of tinea pedis. Br J
Dermatol 1994;130:12-4.
4 Evans EGV, Dodman B, Williamson DM, Brown GJ, Bowen
RG. Comparison of terbinafine and clotrimazole in
treating tinea pedis. BMJ 1993;307:645-7.
5 Evans EGV, James IGV, Seaman RAJ, Richardson MD.
Does naftifine have anti-inflammatory properties? A
double blind comparative study with 1% clotrimazole-1%
hydrocortisone in clinically diagnosed fungal infection of
the skin. Br J Dermatol 1993;129:437-42.
Teaching medical students
about bereavement is hard
Editor—The paper by Saunderson and
Ridsdale and the accompanying commen-
tary by Jewell, about attitudes towards
responding to bereavement, raise several
difficult questions for those teaching under-
graduate medical students.1 We are told by
the doctors interviewed that they were inad-
equately prepared by their medical school
for the task of caring for dying patients. Most
medical schools have paid attention to
teaching this for some time; it follows that
what was taught was inadequate for doctors’
needs. It is difficult to know how to teach
about the experience of the doctors’ grief
reaction to the serious illness and death of a
patient (guilt, sadness, and anger) without
having them experience it.
This takes us to Jewell’s suggestion that
our own and our medical students’ personal
experiences are a source of valuable
learning and insight. That is true, but
harnessing it in a constructive manner may
be a problem. I have had the experience of
students staying away from a course on care
of the dying and bereavement because they
believed (wrongly) that I was going to ask
them to reveal their own experiences of
bereavement to their colleagues. Students
come to us with different degrees of accept-
ance of their losses and abilities to use them
as a learning resource. Finding teachers who
can deal with these issues sensitively enough
may be difficult.
Many medical schools (including my
own) have developed courses for students
that bring them into contact with patients
and potential patients early in their course,
at least partly so that they may retain their
concept of diversity in the population.
Whether we succeed with this aim should be
the subject of research in the future.
This is something that is difficult to teach
to the full satisfaction of the student;
perhaps in the same way that a doctor caring
for a dying patient always has a feeling of
inadequacy, undergraduate teachers will
also have a feeling of inadequacy in how well
they have completed their task.
Jon Fuller senior lecturer (jointly responsible for
undergraduate teaching)
Department of Primary HealthCare and General
Practice, Imperial College School of Medicine,
Chelsea and Westminster Hospital, London
SW10 9NP
j.fuller@ic.ac.uk
1 Saunderson EM, Ridsdale L. General practitioners’
beliefs and attitudes about how to respond to
bereavement: qualitative study [with commentary by D
Jewell]. BMJ 1999;319:293-6. (31 July.)
Cycle helmets
BMA report does not give the whole
picture
Editor—The Child Accident Prevention
Trust was interested to read the report of the
BMA’s Board of Education and Science on
the compulsory use of cycle helmets.1 The
trust agrees with the board’s recommenda-
tions, in that society is not yet ready to accept
legislation in this area, and the other recom-
mendations on the value of educational
efforts to increase the use of cycling in gen-
eral and of helmet wearing.
However, we would have liked to see
more evidence of the effectiveness of
helmets in reducing deaths and brain injury,
which seems to be important in deciding to
what extent helmets should be worn. In the
report this is given a somewhat cursory
review of just over one page, whereas stand-
ards and their verification, and the purchase
and care of helmets, receive eight pages. The
Child Accident Prevention Trust is the main
organisation in Britian concerned solely
with the reduction of accidents and injuries
to children, but its work in this area and in
particular its association with “Headstart” in
the sale of low-cost helmets to schools—
which has so far resulted in the sale of
approximately 28 000 helmets—is not men-
tioned at all.
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The report in the BMJ is also somewhat
unbalanced in that in that it tends to take a
negative approach to the problem.2 The
statement that “a much greater number of
lives would be saved if pedestrians and car
occupants were encouraged to wear bicycle
helmets” is sheer nonsense as it stands, with-
out amplification and qualification.
The Child Accident Prevention Trust is
strongly in favour of the promotion of
cycling by children and of their use of
helmets when doing so, both on the road
and in off the road activities.
Hugh Jackson president
Child Accident Prevention Trust, London
EC1R 3AU
safe@capt.demon.co.uk
1 Board of Education and Science. Cycle helmets. London:
BMA, 1999.
2 Carnall D. Cycle helmets should not be compulsory. BMJ
1999;318:1505. (5 June.)
Summary of electronic responses
The BMA’s recommendation that cycle hel-
mets should not be compulsory1 polarised
opinion.2 Of the 26 electronic letters, 11
were against compulsory helmet wearing
and 10 were in favour.
A Cartmell thinks that car drivers should
wear a helmet “since more head injuries
occur to car occupants and helmets would
be much easier to wear in a car.” Others
referred to a lack of evidence: “The evidence
for the effectiveness of these things is at best
inconclusive and the reduction in cycling
which would ensue from legislation is a
good reason for opposing it” (A Campbell).
Wearing a helmet might even increase the
problem—by analogy, “Helmet wearing for
recreational skiing encourages an increased
velocity through added confidence instilled
and by identification with ski racing, thus
increasing the chance of personal injury and
injury to other skiers and reducing any pro-
tective benefit of the helmet” (D Sim). This
authoritative public health message is
substantiated by the observation that “the
only danger . . . on the road is helmeted
speed demons cutting corners and endan-
gering all” (J Rider).
On the other side of the argument, we
are reminded that “in 1959 motor manufac-
turers and safety experts laughed at Volvo
for introducing seatbelts. It was thought
safer to be thrown clear of a crashing
vehicle” (D Carvel). Expressed in personal
risks, “all it takes is one event with a head
injury to ruin your life” (D Duffield).
Compulsory use of cycle helmets seemed to
have reduced mortality in New Jersey: “In
the year preceding enactment, 14 children
died here as the result of cycle injuries. Dur-
ing the first year of implementation, the
statewide toll was reduced to only two” (AL
Yeager). But “if, as seems likely, deaths fell
because the helmet laws dramatically cut the
number of children who cycle” (D Carnall)
this might not be the right way forward.
Data from Victoria might provide the
answer—if we knew what really happened.
“Nine years on, however, cycling is more
popular in Victoria than it was before” (A
Verrinder); or is it because “nine years after
mandatory introduction in Australia, cyclist
numbers have still not returned to the level
pre-legislation—despite a national popula-
tion increase of well over a million people”
(C Gillham)?
1 Carnall D. Cycle helmets should not be compulsory. BMJ
1999;318:1505. (5 June.)
2 Electronic responses. Cycle helmets should not be
compulsory. eBMJ 1999;318 www.bmj.com/cgi/content/
full/318/7197/1505/a#responses (accessed 27 July
1999).
The coroner service
Coroner service could indeed be
improved
Editor—I recognise the need for society
and the judiciary to be able to check up on
medical practitioners, but I strongly concur
with Pounder’s views that the coroner
service could be improved.1 A 49 year old
patient of the practice where I work died
peacefully at home recently of cerebral
metastases from lung cancer. He had been
ably cared for by his wife and daughters with
help from the district and hospice nurses in
liaison with one of my partners and our
local oncologist. I attended to confirm death,
but as he had not needed to see a doctor in
the last month or so the coroner would not
permit me to issue the death certificate.
After some negotiation and despite being
sympathetic, he did consent to my partner
issuing the death certificate on her return
from holiday four days later, although he
would not have done so had she not been
due back so soon.
There seemed no doubt about our
patient’s identity or place or cause of death,
and there certainly was no hint of foul play.
This case is by no means an isolated one,
and I am sure that many of my general prac-
titioner colleagues are tempted to overlook
the rules in straightforward natural deaths to
protect relatives from interference. I believe
that the public would welcome the oppor-
tunity to express their views and am equally
sure that they would support modernisation
of this archaic but important service.
James Pilpel general practitioner
The Surgery, Tean, Stoke on Trent ST10 4EG
1 Pounder D. The coroner service. BMJ 1999;318:1502-3.
(5 June.)
Inquests often facilitate grief
Editor—Pounder’s editorial on the coroner
service fails to raise important issues in rela-
tion to bereavement and the existing
coroner service.1 There is a conflict of inter-
est between the “enforceable intrusion” of a
coroner’s inquest to ascertain the cause of a
sudden death and the needs of relatives.
A previous editorial in the BMJ stated
that an inquest is conducted at a “time of
greatest grief, distress, and uncertainty,”2 and
yet general practitioners do not routinely
receive necropsy reports from the coroner
and so are not in an informed position to tell
relatives how the person died. Furthermore,
doctors may be inhibited by the standard
admonition regarding a coroner’s report
that the content should not be disclosed to a
third party without consent.3
Pounder correctly questions why so
many inquests are conducted. But inquests
provide relatives with an opportunity to
understand the cause of death, which may
aid in the grieving process after this
traumatic and intimate examination. Indeed,
this information may assist in confirming
the inevitability of death and help to dispel
feelings of doubt, guilt, and anger.4
Rodger Charlton general practitioner principal
The Surgery, Hampton-in-Arden, Solihull B92 0AH
charlton@monfode.demon.co.uk
1 Pounder D. The coroner service. BMJ 1999;318:1502-3.
(5 June.)
2 Turner J, Raphael B. Requesting necropsies. BMJ
1997;314:1499-500.
3 Karunaratne S, Benbow EW. A survey of general
practitioners’ views on autopsy reports. J Clin Pathol
1997;50:548-52.
4 Start RD, Saul CA, Cotton DWK, Mathers NJ, Underwood
JCE. Public perceptions of necropsy. J Clin Pathol
1995;48:497-500.
All sudden infant deaths must be
investigated thoroughly
Editor—Pounder states that the coroner
service should focus “more narrowly on
deaths of legitimate medicolegal interest”
and implies that a reduction in referrals and
necropsies could “reflect a greater sensitivity
to the rights of the next of kin.”1 I am
concerned that such a move might reduce
the coroner’s role in sudden and unexpected
infant deaths, resulting in poorer detection
of cases of child abuse or neglect. This is
highlighted by a development in Australia,
where the coroner’s right to necropsy has
been overturned in its High Court by
parents on religious or ethical grounds.2
Cases of sudden and unexpected infant
death in the United Kingdom are referred to
the coroner for investigation, and the police
are responsible for determining whether
deaths are natural or arise from child abuse
or neglect. Deaths arising from child abuse
or neglect are difficult to detect, even when
minor, but non-lethal, injuries are found at
necropsy.3
There are now reports of cases of infant
death that have been presumed to be natural
(sudden infant death syndrome) but on sub-
sequent presentation of a sibling with child
abuse were found to have been due to infan-
ticide only after further investigations by
several agencies.4 It is accepted that a
postmortem examination alone may not be
able to identify intentional suffocation as a
mechanism unless there are other injuries.
Thus a postmortem examination cannot
differentiate between intentional suffocation
and sudden infant death syndrome (a
diagnosis of exclusion).
I suggest that multiagency investigations
by child death review teams should become
mandatory to help distinguish deaths result-
ing from abuse or neglect from those due to
natural mechanisms.5 The coroner should
initiate such reviews to ensure that deaths
due to abuse are not missed and that living
siblings may be adequately protected from
the abuse that can be meted out by parents
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who kill their children in this way. Recent
data show that a proportion of sudden
infant deaths result primarily from abuse or
neglect (figures of 10% quoted5). It is
therefore in the interests of living and dead
children, as well as innocent parents who
have suffered a natural tragedy, for the
recommendations of the Confidential
Enquiries into Stillbirths and Deaths in
Infancy to be implemented by statute.
Martin Samuels senior lecturer in paediatrics
Academic Department of Paediatrics, North
Staffordshire Hospital, Stoke on Trent ST4 6QG
doctorsamuels@hotmail.com
1 Pounder D. The coroner service. BMJ 1999;318:1502-3.
(5 June.)
2 Green v Graeme Douglas Johnstone State Coroner. Ref
1995 No 4574.
3 Green MA. A practical approach to suspicious death in
infancy—a personal view. J Clin Pathol 1998;51:561-3.
4 Southall DP, Plunkett MCB, Banks MW, Falkov AF,
Samuels MP. Covert video recordings of life-threatening
child abuse: lessons for child protection. Pediatrics
1997;100:735-60.
5 Confidential Enquiry into Stillbirths and Deaths in
Infancy. 3rd Annual report: sudden unexpected deaths in
infancy 1 January-31 December 1994. London: Department
of Health, 1996.
Culturally sensitive care for the dying is
basic human right
Editor—In many traditions the concept of “a
good end” has reality and significance. This is
particularly true for Muslims. Much time and
energy will be invested by family and friends
to help ensure that the dying end the earthly
phase of their existence in a state of peace in
both their internal and their external worlds.
Internally, this involves inculcating in the
dying a sense of hope and optimism in Allah’s
forgiveness, mercy, and reward. Externally,
this involves setting matters right with one’s
relatives and friends while the opportunity
still exists. Those who are fortunate enough
to die in such a state are, within the Muslim
paradigm, successful. On death there is a
communal responsibility to lay the dead
person to rest swiftly and with dignity.
The hope for a good end is the silent life-
long prayer of many people, yet in the course
of our daily work we are reminded that
achieving this basic human right is often diffi-
cult for British Muslims. We welcome Pound-
er’s editorial,1 recognising how deeply dis-
turbing a coroner’s investigation and the
necropsy that often follows can be for those
from certain religious traditions.2
We would agree that the coroner’s
service is “a relic in need of reform,” but it is
just one of many issues that need to be tack-
led if we are to deliver culturally competent
care to the dying and their families. Hospital
visiting restrictions should be more flexible,
the rule of two visitors per bed being
inappropriate for dying patients from
cultures in which visiting such people is
regarded as a religious obligation. In
addition, appropriate hospital prayer facili-
ties should be available for patients and their
relatives and visitors.
The importance of a prompt burial for
Jews and Muslims must be recognised, and
systems put in place to facilitate this practice,
such as the ability to register and bury one’s
dead at weekends and on public holidays.
Perhaps the single most important change
that will result in culturally sensitive care is a
greater emphasis on transcultural medicine
in the medical curriculum; tomorrow’s clini-
cians and health policymakers would then
have the opportunity to understand the
range of needs of dying patients found in
modern day pluralist Britain.
Aziz Sheikh clinical research fellow
Imperial College School of Medicine, London
W2 1PG
aziz.sheikh@ic.ac.uk
A R Gatrad consultant paediatrician
Manor Hospital, Walsall WS2 9PS
Sangeeta Dhami locum general practitioner
GP Direct, West Harrow, Middlesex HA5 4EA
1 Pounder D. The coroner service. BMJ 1999;318:1502-3.
(5 June.)
2 Spitzer J. A guide to the orthodox Jewish way of life for healthcare
professionals. 2nd ed. London: Spitzer, 1998.
A national service would be more
consistent
Editor—In his editorial Pounder suggests
that the coroner’s service could be vastly
improved by having a national system in
place rather than the local services that cur-
rently exist.1 Our work on the Confidential
Enquiry into Stillbirths and Deaths in
Infancy incorporates two health regions,
and we rely on the coroners to provide us
with information about fetal and infant
deaths. We have found many local variations.
One difference is that in some districts a
specialist perinatal pathologist performs the
necropsies on babies while in others this is
not the case. Such specialist reports provide
valuable and sometimes previously unknown
information on the cause of death and can
help in the management of the future
pregnancies of the parents of children who
have died.2–4 The Royal College of Patholo-
gists strongly recommends that necropsies
on infants should be carried out by a special-
ist pathologist,5 and we at the Confidential
Enquiry into Stillbirths and Deaths in Infancy
agree with this. This is true of all cases, includ-
ing (and perhaps especially) those reported
to the coroner.
We have always found the coroners and
their staff to be extremely helpful and
supportive of our work. We agree with
Pounder, though, that a national system
would be far more beneficial and consistent,
both for the families of the infants who have
died and for data collection purposes.
Judith Levitan information manager, CESDI North
Thames West
nwthames@cesdi.org.uk
Brenda K Dines database manager, CESDI North
Thames East
North Thames Perinatal Public Health, Northwick
Park Hospital, Harrow, Middlesex HA1 3UJ
1 Pounder D. The coroner service. BMJ 1999;318:1502-3.
(5 June.)
2 Thornton CM, O’Hara MD. A regional audit of perinatal
and infant autopsies in Northern Ireland. Br J Obstet
Gynaecol 1998;105:18-23.
3 Stambouly JJ, Kahn E, Boxer RA. Correlation between
clinical diagnoses and autopsy findings in critically ill chil-
dren. Pediatrics 1993;92:248-51.
4 Rushton DI. Prognostic role of the perinatal postmortem.
Br J Hosp Med 1994;52:450-4.
5 Confidential Enquiry into Stillbirths and Deaths in
Infancy. 5th Annual report: maternal and child health.
London: Maternal and Child Health Research Consor-
tium, 1998.
Attribution of time lag theory
to explain French paradox
Editor—After the publication of our paper
in the BMJ of 29 May on why mortality from
heart disease is low in France (the French
paradox),1 it was drawn to our attention that
the time lag explanation that we set out in
our paper had previously been put forward,
by Marion Nestle, in a letter to the Lancet in
1992.2 We were not aware of this attribution,
and we would have cited it if we had been.
Malcolm Law reader
Nicholas Wald professor
Wolfson Institute of Preventive Medicine,
St Bartholomew’s and the Royal London School of
Medicine and Dentistry, London EC1M 6BQ
1 Law M, Wald N. Why heart disease mortality is low in
France: the time lag explanation. BMJ 1999;318:1471-80.
(29 May.)
2 Nestle M. Wine and coronary heart disease. Lancet
1992;40:314-5.
Pens are certainly more
portable than computers
Editor—My normal handwriting is so bad
that a physician friend has deservedly
commented, “Your only attribute for being a
physician is your handwriting.”1 Yet this
friend’s writing is admirably clear.
A while back, on reading a note that I
had written to myself, I found that not only
could I not decipher it but I had no idea
what it was about, even from the context. So
it was a matter of either learning touch typ-
ing or improving my handwriting; certainly
handwriting seemed more versatile. I did
some reading and found that the humanist
script (used by monks for fast writing) was
legible; the modern descendant is italic
script.
I took an evening class in calligraphy
and soon found myself rapped over the
knuckles by the teacher, for “calligraphy is
an art form and not to be used for everyday
writing.” Anyway, I use italic for all
correspondence except electronic mail, take
a photocopy, and have found that people
seem to prefer the personal touch. A pen
weighs much less than a laptop and printer
for trips.
Apparently there has been a resurgence
of ink pens among undergraduates in the
United States. I have surveyed people at
recent physics conferences: it’s obvious that
the great majority in this computer-happy
trade use pens and paper and pocket paper
diaries. Perhaps correspondents could tell
me of good italic ink pens now that my
favourite is being discontinued.
Len Finegold physicist
Drexel University, Philadelphia, PA 19104, USA
L@Drexel.edu
1 Dunea G. Beastly handwriting. BMJ 1999;319:65. (3 July.)
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